Fair market value assessments for engagements

Introduction

Fair Market Value (FMV) assessments for engagements refer to the process of determining the reasonable economic value of services, products, technologies, intellectual property or commercial arrangements involved in a business engagement. In biotechnology and pharmaceutical industries, such assessments are particularly important because commercial transactions frequently involve research collaborations, licensing agreements, clinical research services, technology transfers, consultancy arrangements and the supply of specialised biological materials.

Fair market value represents the price that an asset or service would reasonably command between willing and independent parties dealing at arm's length, with neither party being compelled to enter into the transaction and both having reasonable knowledge of the relevant facts.

In biotechnology engagements, FMV assessments help prevent excessive payments, underpricing, financial manipulation, conflicts of interest and improper commercial arrangements. They also promote transparency in transactions involving research institutions, pharmaceutical companies, biotechnology manufacturers and healthcare professionals.

In India, FMV assessments are relevant under income tax legislation, company law, transfer pricing regulations, competition law and contractual principles.

Meaning and importance of fair market value assessments

Fair Market Value assessment involves determining whether the price or compensation agreed upon in a commercial engagement reflects the reasonable market value of the relevant goods, services or rights.

For example, when an Indian biotechnology company enters into a research collaboration with a foreign pharmaceutical company, the parties may need to determine the fair value of research services, laboratory facilities, intellectual property rights and technical expertise.

The assessment helps establish whether the agreed compensation is commercially reasonable.

The major objectives include:

Preventing artificial inflation or reduction of transaction values.

Ensuring transparency in commercial engagements.

Protecting investors and shareholders.

Preventing conflicts of interest.

Ensuring compliance with tax and transfer pricing regulations.

Establishing reasonable compensation for research and consultancy services.

Supporting fair competition in biotechnology markets.

Legal framework governing fair market value assessments in India

1. Income-tax Act, 1961

The Income-tax Act, 1961 historically provided important provisions governing the determination of fair market value in commercial and financial transactions.

Section 92 deals with the computation of income arising from international transactions between associated enterprises in accordance with the arm's length principle.

Section 92C provides methods for determining the arm's length price, including:

Comparable uncontrolled price method.

Resale price method.

Cost-plus method.

Profit split method.

Transactional net margin method.

Other prescribed methods.

These provisions are relevant when biotechnology companies enter into international research agreements, intellectual property licensing arrangements or technology transfer transactions with associated enterprises.

Current-law note: The Income-tax Act, 2025 came into force on 1 April 2026, replacing the 1961 Act. Accordingly, references to the 1961 Act are historical or relevant to earlier assessment years; current transactions must be examined under the corresponding provisions of the 2025 Act and applicable rules.

2. Companies Act, 2013

The Companies Act, 2013 contains provisions governing related-party transactions, valuation and corporate accountability.

Section 188 regulates specified related-party transactions and establishes requirements concerning board approval and, where applicable, shareholder approval.

Section 247 provides for the appointment and regulation of registered valuers for valuations required under the Act.

In biotechnology engagements, these provisions may become relevant when a company enters into research contracts, technology licensing agreements or consultancy arrangements with related entities.

3. Foreign Exchange Management Act, 1999

The Foreign Exchange Management Act, 1999 regulates foreign exchange transactions in India.

FMV assessments may become relevant in cross-border transactions involving the issue or transfer of shares, foreign investment and certain other capital transactions.

The Reserve Bank of India establishes applicable pricing guidelines and reporting requirements.

For example, when a biotechnology start-up issues shares to a foreign investor, valuation requirements may apply depending on the nature of the transaction and the applicable FEMA regulations.

4. Competition Act, 2002

The Competition Act, 2002 regulates anti-competitive agreements, abuse of dominant position and combinations.

Fair valuation is relevant where commercial engagements involve exclusive licensing, technology access, distribution arrangements or other transactions that may affect market competition.

Section 4 prohibits abuse of dominant position, including certain unfair or discriminatory pricing practices.

5. Indian Contract Act, 1872

The Indian Contract Act, 1872 establishes the legal principles governing contractual relationships.

Sections 10 and 23 are relevant to valid agreements and agreements opposed to public policy or prohibited by law.

Section 73 addresses compensation for loss or damage caused by breach of contract.

In biotechnology engagements, contractual parties should clearly establish the scope of services, payment obligations, valuation methodology and mechanisms for resolving valuation disputes.

Methods of fair market value assessment

1. Comparable uncontrolled price method

This method compares the price charged in a controlled transaction with the price charged in a comparable transaction between independent parties.

For example, if a biotechnology company licenses a diagnostic technology to an associated foreign company, the royalty rate may be compared with similar independent licensing arrangements.

2. Cost-plus method

Under this method, the total cost of providing a service is calculated and an appropriate profit margin is added.

It is particularly useful for biotechnology research services, laboratory testing and contract manufacturing engagements.

3. Income approach

The income approach determines value by estimating the future economic benefits expected from an asset or engagement.

It may be used for valuing biotechnology patents, research technologies and commercially promising biological innovations.

Discounted Cash Flow (DCF) analysis is a common technique under this approach.

4. Market approach

The market approach determines value by comparing similar transactions involving comparable goods, services or intellectual property.

It is particularly useful when reliable market information is available.

5. Asset-based approach

This method determines value by examining the underlying assets and liabilities associated with a business or engagement.

It may be relevant when valuing biotechnology research facilities, laboratory equipment and specialised manufacturing infrastructure.

Application of FMV assessments in biotechnology engagements

Fair market value assessments have particular significance in biotechnology because commercial engagements frequently involve specialised services and intangible assets.

Research and development agreements: FMV assessments help determine reasonable compensation for laboratory services, research personnel and scientific expertise.

Intellectual property licensing: They establish commercially reasonable royalty payments for patents, proprietary biological processes and biotechnology platforms.

Clinical research agreements: They help determine appropriate payments for clinical trial management, research facilities and professional services.

Technology transfer arrangements: They assist in determining the value of transferred technologies, manufacturing processes and technical know-how.

Consultancy engagements: They help establish reasonable compensation for scientific consultants, medical experts and biotechnology advisers.

Important case laws and judicial principles

1. CIT v. Glaxo SmithKline Asia (P) Ltd. (2010)

The Supreme Court examined issues concerning transfer pricing and the tax treatment of transactions between associated enterprises.

The judgment highlighted the importance of examining whether related-party transactions are conducted at commercially appropriate prices under the applicable tax framework.

Relevance: Biotechnology companies entering into related-party research, consultancy and licensing arrangements should maintain appropriate documentation supporting the commercial reasonableness of their transaction values.

2. Vodafone International Holdings BV v. Union of India (2012)

The Supreme Court examined the taxation of an offshore transaction involving the transfer of shares of a foreign company.

The judgment discussed the importance of examining the legal substance and structure of cross-border transactions.

Relevance: Biotechnology companies involved in international investments, corporate restructuring and intellectual property transactions must carefully examine transaction structures and applicable valuation and tax requirements.

3. DIT v. Morgan Stanley & Co. Inc. (2007)

The Supreme Court examined transfer pricing principles relating to international transactions between associated enterprises.

The Court discussed the arm's length principle and the circumstances in which an appropriate transfer pricing analysis may determine whether additional profits are attributable to an Indian entity.

Relevance: Indian biotechnology subsidiaries providing research, technical support or contract development services to foreign associated enterprises must establish appropriate arm's length compensation.

4. Cushman & Wakefield (India) Pvt. Ltd. v. ACIT (2014)

The Delhi High Court considered transfer pricing adjustments involving international transactions and the determination of arm's length pricing.

The judgment emphasised the importance of examining the actual nature of services and the evidence supporting their economic value.

Relevance: Biotechnology companies claiming payments for research, consultancy, technical assistance or management services should maintain evidence demonstrating that the services were actually provided and that the compensation was commercially justified.

5. Vodafone Essar Ltd. v. Dispute Resolution Panel (2011)

The Delhi High Court examined transfer pricing issues involving international transactions and the determination of arm's length pricing.

The decision is relevant to the requirement that transfer pricing assessments should be based on appropriate comparables and a reasoned analysis of the transaction.

Relevance: Biotechnology engagements involving international research collaborations and licensing arrangements should use reliable comparable transactions and appropriate valuation methods rather than arbitrary pricing assumptions.

Challenges in fair market value assessments

FMV assessments in biotechnology engagements involve several practical and legal difficulties.

First, biotechnology technologies are highly specialised, making it difficult to identify genuinely comparable market transactions.

Second, the commercial value of research projects may remain uncertain because successful product development is not guaranteed.

Other important challenges include:

Difficulty in valuing early-stage biotechnology patents.

Lack of reliable market comparables.

Uncertainty regarding future royalty income.

Differences in international valuation standards.

Conflicts of interest in related-party transactions.

Inadequate documentation of research services.

Difficulty in estimating the commercial value of scientific know-how.

Suggestions for strengthening FMV assessment mechanisms

Companies should adopt transparent and scientifically supported valuation procedures for biotechnology engagements.

Independent registered valuers and qualified financial professionals should be involved wherever legally required or commercially appropriate.

Important measures include:

Maintaining detailed valuation reports.

Using reliable market comparables.

Documenting research activities and services performed.

Applying appropriate transfer pricing methods.

Reviewing related-party transactions independently.

Establishing clear contractual payment mechanisms.

Updating valuations when material commercial circumstances change.

Companies should also maintain records of intellectual property ownership, research expenditure, licensing rights and expected commercial benefits.

Conclusion

Fair Market Value assessments for engagements are essential for ensuring transparency, accountability and commercial fairness in biotechnology and pharmaceutical transactions. They help determine reasonable compensation for research services, intellectual property licensing, clinical research, technology transfers and consultancy arrangements.

Indian legislation, including the income tax framework, Companies Act, 2013, FEMA, 1999, Competition Act, 2002 and Indian Contract Act, 1872, provides important legal principles governing valuation and commercial transactions.

Judicial decisions such as CIT v. Glaxo SmithKline Asia (P) Ltd., DIT v. Morgan Stanley & Co. Inc. and Vodafone International Holdings BV v. Union of India demonstrate the importance of proper transaction analysis, arm's length pricing and legal compliance.

An effective FMV assessment framework must combine independent valuation, reliable financial information, transparent contractual arrangements and regulatory supervision. Such a framework can strengthen investor confidence, prevent financial manipulation and promote sustainable commercial relationships in India's biotechnology industry.